December 19, 2016 11:36 AM EST
R&D

Af­ter an R&D odyssey filled with set­backs, Clo­vis wins an FDA OK for ru­ca­parib

John Carroll

Editor & Founder

Clo­vis On­col­o­gy $CLVS won some re­demp­tion to­day, gain­ing an ac­cel­er­at­ed ap­proval for its first drug and set­ting it on a short path to com­mer­cial­iza­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times